TwinStrand
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Life Sciences, DNA sequencing
- Founded
- 2016 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- TwinStrand Biosciences Inc Seattle business license
- Stage
- Seed
Elon Musk's Starlink swagger, SpaceX vs. the cloud giants, and Seattle’s tech universe revisited
This week: SpaceX reports its first quarter as a public company, and Elon Musk says Starlink could deliver a majority of the world's internet within a decade, leveraging production facilities in Redmond. Musk also explains the company's data center ambitions, calling terrestrial infrastructure a trivial problem next to reusable rockets. Plus: we bring two Washington tech universe posters into the studio, 17 years apart. The 2009 original turns up gems including Boeing's unlikely connection to Classmates.com, a 1990s forerunner to Facebook. The 2009 poster also brings back memories of Teledesic, the Craig McCaw venture backed by Bill Gates that tried…
Kevin Conroy Resigns from Adaptive Biotechnologies Board; Tagboard COO Tyler Singletary Steps Down; Ron Andrews Named TwinStrand CEO
Kevin Conroy resigned from the board of Adaptive Biotechnologies, and Tagboard's COO Tyler Singletary is stepping down. Additionally, Ron Andrews was named CEO of TwinStrand Biosciences, while David Meininger stepped down as CEO of Link Immunotherapeutics.
TwinStrand Biosciences CEO Jesse Salk Steps Down Amid Layoffs; Chad Brown Named Interim CEO
TwinStrand Biosciences co-founder Jesse Salk has stepped down as CEO but will remain chief scientific officer and board member, with Chad Brown named interim CEO amid reported layoffs cutting nearly 50% of the workforce at the Seattle-based gene sequencing startup. The company, founded seven years ago and backed by a $50 million Series B round in 2021, declined to comment on the layoffs.
A-Alpha Bio raises $20M Series A led by Madrona to expand Seattle lab and scale protein-discovery platform
University of Washington spinout A-Alpha Bio raised $20 million in Series A funding led by Madrona Venture Group to expand downtown Seattle lab space and grow its machine-learning team for its protein-discovery platform. The company combines computational tools and yeast-based experiments to generate large protein-interaction datasets used to predict therapeutic protein candidates for diseases including COVID-19.
Former Tech Leaders Join Biotech: Isilon Founder Sujal Patel, Ex-Microsoft Terry Myerson and Others Lead AI-Driven Life Sciences Startups
Several former software and tech executives are moving into biotech and life sciences startups, bringing AI, machine learning, and tech-style business models to companies that analyze proteins, microbes, and medical records. Their tech backgrounds are reshaping product development and funding approaches at firms such as Nautilus Biotechnology, Truveta, insitro and Viome.
Madrona Venture Group’s Steve Singh Details Six Post-COVID Tech Trends and Reasons for Hope on GeekWire Podcast
Steve Singh, managing director of Madrona Venture Group and former CEO of Docker and Concur, joined GeekWire to discuss reasons for hope and six technology trends to watch as the Pacific Northwest emerges from the pandemic, in a special episode tied to the 2021 virtual GeekWire Awards.
TwinStrand Biosciences, led by Jesse Salk, raises $50M Series B from Section 32 to scale ultra-accurate gene-sequencing
TwinStrand Biosciences, co-founded and led by Jesse Salk, raised $50 million in a Series B led by Section 32 to expand its high-accuracy gene-sequencing technology for detecting rare mutations with applications in cancer detection, therapy monitoring, and safety testing.
Phase Genomics CEO Ivan Liachko shifts company to R&D focus after pandemic hits revenue; one furlough, no layoffs
Phase Genomics, a five-year-old University of Washington spinoff led by CEO Ivan Liachko, shifted to skeleton lab crews and remote work during the pandemic, cutting revenue and furloughing one employee while focusing R&D inward to adapt and continue innovating. The company is adjusting its genomics technology amid Seattle's biotech disruption and exploring ways to help with COVID-19 research.
People
-
Jesse Salk Founder, Co-founder and CEO
